• News
  • FAQ
  • Investors
JanOne
  • Why We Exist
  • Pipeline
  • The Pain Truth
  • About PAD
  • Our Company
  • News
  • FAQ
  • Investors
  • FOLLOW THE PROGRESS

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Shareholder Letter
    • FAQ
  • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 21, 2023 11:30am EDT

JanOne to Present at the Dawson James 8th Annual Investment Conference

Aug 31, 2023 1:30pm EDT

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

Aug 29, 2023 1:30pm EDT

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

Aug 25, 2023 2:30pm EDT

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

Aug 22, 2023 5:30pm EDT

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 18, 2023 7:00pm EDT

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 18, 2023 12:42pm EDT

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

Jun 28, 2023 8:30am EDT

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

Apr 18, 2023 8:30am EDT

JanOne Completes Pre-IND Meeting with FDA on Jan123

Apr 13, 2023 8:30am EDT

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next
RSS
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
JanOne

JanOne is a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. As a result, we hope to reduce the need for prescribing dangerous opioid drugs. Our first drug candidate is a treatment for Peripheral Arterial Disease (PAD), a condition that can cause severe pain and affects over 8.5 million people in the US alone.

The company trades under the symbol JAN on the NASDAQ and continues to independently operate its subsidiary business – Appliance Recycling Centers of America, Inc (ARCA).

Latest News

JanOne on Twitter

  • Why We Exist
  • Pipeline
  • The Pain Truth
  • About PAD
  • Our Company
  • News
  • FAQs
  • Investors
  • Contact